Botulinum toxin for Achalasia

Phase-Based Progress Estimates
Achalasia+1 More
Patient reported outcomes - Other
All Sexes
What conditions do you have?

Study Summary

This trial compared the effects of two treatments for achalasia, a condition that affects the esophagus.

Eligible Conditions
  • Achalasia

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
dysphagia score

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Botulinum toxin
1 of 2
Botulinum toxin and dilation
1 of 2

Active Control

50 Total Participants · 2 Treatment Groups

Primary Treatment: Botulinum toxin · No Placebo Group · Phase 4

Botulinum toxinActiveComparator Group · 3 Interventions: Patient reported outcomes, Barium esophagram, Botulinum toxin type A · Intervention Types: Other, DiagnosticTest, Drug
Botulinum toxin and dilationActiveComparator Group · 4 Interventions: Patient reported outcomes, Endoscope balloon dilator, Barium esophagram, Botulinum toxin type A · Intervention Types: Other, Device, DiagnosticTest, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
768 Previous Clinical Trials
592,106 Total Patients Enrolled
2 Trials studying Achalasia
90 Patients Enrolled for Achalasia
Dhyanesh Patel, MDPrincipal InvestigatorVanderbilt University Medical Center
2 Previous Clinical Trials
123 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.